• Alias: APC8015
    • A cell-based vaccine composed of autologous antigen-presenting peripheral blood mononuclear cells that have been exposed to a recombinant protein consisting of GM-CSF fused to PAP, a protein expressed by prostate cancer cells resulting in antitumor T-cell response against tumor cells
    • FDA approved for the treatment of asymptomatic or minimally symptomatic metastatic castrate–resistant (hormone-refractory) prostate cancer
    • Recommended dose: Each dose contains >50 million autologous CD54+ cells (leukapheresis) activated with PAP-GM-CSF; dose given at â™2 week intervals for a total of three doses. Premedications with acetaminophen PO and diphenhydramine are needed.
    Other topics in Targeted and Immunotherapy Agents